However, these mainstream therapies face critical limitations including the rapid emergence of drug resistance, FKS1/FKS2 gene mutations reducing -1,3-glucan synthase affinity, Targeted enzyme (Erg11p) modification, overexpression of efflux pumps (CDR1, MDR1), and upregulation of the ergosterol pathway mediate azole resistance (Pristov and Ghannoum, 2019)
The pharmacokinetic properties of GLP1R agonists, which typically require injection, remain a factor limiting treatment adherence, thus highlighting the relevance of developing oral and other non-invasive formulations
2004 May 15;92(2):285-95
Jackson, MR
C., Reivich, M
PheWAS analysis results suggest that PNKP may affect body composition, such as muscle mass and fat metabolism, with more significant effects in females, indicating that sex differences must be considered to ensure precise and safe therapeutic outcomes